Travere Therapeutics
TVTX
218 hedge funds and large institutions have $1.77B invested in Travere Therapeutics in 2025 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 88 increasing their positions, 57 reducing their positions, and 23 closing their positions.
159% more call options, than puts
Call options by funds: $29.5M | Put options by funds: $11.4M
91% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 23
54% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 57
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
11% more funds holding
Funds holding: 197 → 218 (+21)
7% more capital invested
Capital invested by funds: $1.66B → $1.77B (+$117M)
0.21% less ownership
Funds ownership: 110.75% → 110.55% (-0.21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$70.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$36.7M |
| 3 |
AC
Armistice Capital
New York
|
+$30.7M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$17.7M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$41.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35.1M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$26.6M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$21.6M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$17.9M |
TVTX Hedge Fund Activity: Q1 2025 in Review
218 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2025, worth a combined $1.77B — up 7.1% from $1.66B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new TVTX positions and 23 closed out — a net gain of 21 holders — while 88 added to existing stakes and 57 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $70.4M. The largest seller was Rock Springs Capital Management, cutting an estimated $41.7M.
- 218 institutional investors held Travere Therapeutics (TVTX) as of Q1 2025, up from 197 in Q4 2024.
- Funds reported $1.77B of Travere Therapeutics stock for Q1 2025, up 7.1% quarter-over-quarter.
- 44 funds opened new Travere Therapeutics positions in Q1 2025 and 23 closed out, a net change of +21 holders.
- The largest Travere Therapeutics buyer in Q1 2025 was Janus Henderson Group, an estimated $70.4M added.
- The largest Travere Therapeutics seller in Q1 2025 was Rock Springs Capital Management, an estimated $41.7M sold.
Based on aggregated 13F filings for Q1 2025.